Bone Marrow Transplant News and Research

RSS

Inflammation-Induced Epigenetic Changes Limit Intestinal Stem Cell Regeneration

Researchers from the University of Michigan, Baylor College of Medicine, and other affiliated institutions have found that intestinal stem cells (ISCs) are permanently altered by inflammation in the gut, which limits the cells' capacity to repair the gut even after the inflammation has subsided.

4 Sep 2024

Melbourne Researchers Achieve Breakthrough in Creating Human-Like Blood Stem Cells

Melbourne researchers have made a world first breakthrough into creating blood stem cells that closely resemble those in the human body.

3 Sep 2024

New Clinical Trial Offers Path to Sickle Cell Cure

The most recent results from a clinical trial were given by researchers in an effort to find a cure for sickle cell disease, a painful genetic blood illness that has few available treatments.

17 Jun 2024

Microbial Sensor Unlocks Path to Personalized Blood Stem Cell Therapy

A microbial sensor that helps identify and fight bacterial infections also plays a key role in the development of blood stem cells, valuable new insight in the effort to create patient-derived blood stem cells that could eliminate the need for bone marrow transplants.

21 Dec 2023

Microbial Sensor Plays Key Role in Blood Stem Cell Development

20 Dec 2023

New Proof-of-Concept Model for Delivering Gene Editing Tools to Treat Blood Disorders

In a step forward in the development of genetic medicines, researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body.

28 Jul 2023

The Pivotal Role of Combinatorial CRISPR Gene Editing in the Elimination of HIV-1 Infection

Recent research from Temple University’s Lewis Katz School of Medicine and the University of Nebraska Medical Center demonstrates that gene-editing therapy aimed at two targets - HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that aids the virus getting into cells—can effectively eliminate HIV infection.

2 May 2023

Improved efficacy of advanced genome editing with machine learning

Researchers at the Wellcome Sanger Institute have developed a new tool to estimate the probability of successfully introducing a gene-edited DNA sequence into a cell’s genome using the prime editing method.

17 Feb 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

31 Jan 2023

Pioneering gene editing approach could lead to new treatments for CTLA-4 insufficiency

A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.

From University College London 27 Oct 2022

Biochemical signals sent from cell to cell play a key role in deciding their fate

Scientists have found a way to prove that biochemical signals sent from cell to cell play an important role in determining how those cells develop.

24 Dec 2021

300 million grant enables the establishment of new international stem cell research center

A grant from the Novo Nordisk Foundation of up to 300 million euro now enables the establishment of a major international research center focused on stem cell medicine.

20 Dec 2021

Next-generation sequencing for minimal residual disease proven more sensitive than flow cytometry

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

2 Dec 2021

Pioneering gene therapy has long-lasting effects on children with deadly immune disorder

Over a decade ago, UCLA physician-scientists began using a pioneering gene therapy they developed to treat children born with a rare and deadly immune system disorder. They now report that the effects of the therapy appear to be long-lasting, with 90% of patients who received the treatment eight to 11 years ago still disease-free.

18 Oct 2021

Severe genetic immunodeficiency reversed by a rare DNA change

Researchers have revealed how a rare DNA change rebalanced the immune system of patients with a life-threatening genetic immunodeficiency.

2 Feb 2021

Somatic mutation acts as natural gene therapy in patients with GATA2 deficiency

Researchers affiliated with the Center for Cell-Based Therapy (CTC) in Ribeirão Preto, Brazil, have identified for the first time a non-hereditary mutation in blood cells from a patient with GATA2 deficiency, a rare autosomal disease caused by inherited mutations in the gene that encodes GATA-binding protein 2 (GATA2).

18 Nov 2020

Researchers identify a new solution for treating ligament injuries

Ligament injuries that affect scores of regular citizens and athletes are sidelined every year. Added to this, recovery is painful and takes a long time and, at times, a return to normal function is never achieved because of the formation of scars—an aspect that makes ligament injuries inclined to more damage.

4 Nov 2020

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.

24 Jul 2020

Developments in Engineered T Cells for Type 1 Diabetes

AZoLifeSciences speaks to Professor David J. Rawlings from the Seattle children's hospital about recent developments in engineered T cells for type 1 diabetes.

23 Jun 2020